Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEVIATE delayed-start study of eptinezumab in episodic cluster headache
jRCT2041210133Completed
- Sponsor
- Lundbeck
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of eptinezumab in Cluster Headache (CH) (2 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline in the number of weekly attacks, averaged over Weeks 1-2. Started May 2022; status: completed.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on jRCT2041210133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210133.